Liguang Lou

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>

Shu Tian, Haitian Quan, Chengying Xie et al. · Cancer Science · 2011 · 521 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Chengying Xie, Xiaozhe Wan, Haitian Quan et al. · Cancer Science · 2018 · 371 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

Xin Li, Changyong Yang, Hong Wan et al. · European Journal of Pharmaceutical Sciences · 2017 · 227 citations

Medicine, Medicinal Chemistry, Oncology +13

Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity

Fuchun Xie, Hongbing Zhao, Lizhi Zhao et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 181 citations

Pharmacy, Medicinal Chemistry, Oncology +14

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

Xuejing Yao, Jing Jiang, Xin Wang et al. · Breast Cancer Research and Treatment · 2015 · 112 citations

Pharmacy, Medicinal Chemistry, Oncology +14